[SCHEDULE 13D/A] Senti Biosciences, Inc. SEC Filing
Celadon Partners disclosed a 45.0% beneficial ownership stake in Senti Biosciences, Inc. (SNTI), reporting ownership of 13,404,441 shares, which includes 3,627,441 shares issuable upon exercise of warrants subject to a 45% ownership cap. The percentage is calculated using 26,160,206 shares outstanding as of July 31, 2025. The filing (Amendment No. 2 to Schedule 13D) states Celadon intends to continue preliminary discussions with Senti about a potential financing and may seek changes to capital structure and Board composition, including potential additional Board representation. Celadon also reserves the right to buy or sell securities or pursue hedging or other actions as circumstances evolve.
Celadon Partners ha dichiarato una partecipazione beneficiaria del 45,0% in Senti Biosciences, Inc. (SNTI), indicando la detenzione di 13.404.441 azioni, comprensive di 3.627.441 azioni esercitabili tramite warrant soggetti a un limite di propriet脿 del 45%. La percentuale 猫 stata calcolata su 26.160.206 azioni in circolazione al 31 luglio 2025. La comunicazione (Emendamento n. 2 al Modulo 13D) indica che Celadon intende proseguire le discussioni preliminari con Senti riguardo a un possibile finanziamento e potrebbe richiedere modifiche alla struttura del capitale e alla composizione del Consiglio, inclusa una possibile rappresentanza aggiuntiva nel Board. Celadon si riserva inoltre il diritto di acquistare o vendere titoli o di adottare operazioni di copertura o altre azioni in base all鈥檈volversi delle circostanze.
Celadon Partners revel贸 una participaci贸n beneficiaria del 45,0% en Senti Biosciences, Inc. (SNTI), reportando la posesi贸n de 13.404.441 acciones, que incluyen 3.627.441 acciones susceptibles de emitirse al ejercer warrants sujetos a un l铆mite de propiedad del 45%. El porcentaje se calcula sobre 26.160.206 acciones en circulaci贸n al 31 de julio de 2025. La presentaci贸n (Enmienda n.潞 2 al Anexo 13D) indica que Celadon pretende continuar las conversaciones preliminares con Senti sobre un posible financiamiento y podr铆a buscar cambios en la estructura de capital y en la composici贸n del Consejo, incluida la posible representaci贸n adicional en el Board. Celadon tambi茅n se reserva el derecho de comprar o vender valores o de llevar a cabo coberturas u otras acciones seg煤n evolucione la situaci贸n.
Celadon Partners電� Senti Biosciences, Inc.(SNTI)鞚� 45.0% 鞁れ 靻岇湢 歆�攵勳潉 瓿奠嫓頃橂┌ 13,404,441欤�毳� 氤挫湢頃橁碃 鞛堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞚� 欷戩棎電� 靻岇湢 頃滊弰 45%臧� 鞝侅毄霅橂姅 鞗岆煱韸� 頄夓偓搿� 氚滍枆 臧�電ロ暅 3,627,441欤�臧� 韽暔霅橃柎 鞛堨姷雼堧嫟. 牍勳湪鞚� 2025雲� 7鞗� 31鞚� 旮办 鞙犿喌 欤检嫕靾� 26,160,206欤茧ゼ 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�. 鞝滌稖靹滊(鞀れ紑欷� 13D 靾橃爼靹� 2順�)鞐� 霐半ゴ氅� Celadon鞚� 鞛犾灛鞝� 鞛愱笀臁半嫭鞐� 雽�頃� Senti鞕� 鞓堧箘 順戩潣毳� 瓿勳啀頃� 瓿勴殟鞚措┌, 鞛愲掣 甑“ 氚� 鞚挫偓須� 甑劚 氤�瓴�(於旉皜 鞚挫偓 靹犾瀯 臧�電レ劚 韽暔)鞚� 氇儔頃� 靾� 鞛堧嫟瓿� 氚濏様鞀惦媹雼�. 霕愴暅 靸來櫓 氤�頇旍棎 霐半澕 歃濌秾鞚� 毵れ垬路毵る弰頃橁卑雮� 項れ 霌� 雼るジ 臁办箻毳� 旆暊 甓岆Μ毳� 氤挫湢頃滊嫟瓿� 氇呾嫓頄堨姷雼堧嫟.
Celadon Partners a d茅clar茅 une participation b茅n茅ficiaire de 45,0 % dans Senti Biosciences, Inc. (SNTI), indiquant d茅tenir 13 404 441 actions, dont 3 627 441 actions susceptibles d鈥櫭猼re 茅mises 脿 l鈥檈xercice de warrants soumis 脿 un plafond de d茅tention de 45 %. Le pourcentage est calcul茅 sur 26 160 206 actions en circulation au 31 juillet 2025. Le d茅p么t (Amendement n掳2 au Schedule 13D) pr茅cise que Celadon a l鈥檌ntention de poursuivre les discussions pr茅liminaires avec Senti au sujet d鈥檜n 茅ventuel financement et pourrait demander des modifications de la structure du capital et de la composition du conseil d鈥檃dministration, y compris une repr茅sentation suppl茅mentaire 茅ventuelle. Celadon se r茅serve 茅galement le droit d鈥檃cheter ou de vendre des titres ou d鈥檈ngager des op茅rations de couverture ou autres selon l鈥櫭﹙olution des circonstances.
Celadon Partners gab einen wirtschaftlichen Eigentumsanteil von 45,0 % an Senti Biosciences, Inc. (SNTI) bekannt und meldete den Besitz von 13.404.441 Aktien, darunter 3.627.441 Aktien, die durch Aus眉bung von Warrants ausgebbar sind und einer Besitzobergrenze von 45 % unterliegen. Die Prozentangabe basiert auf 26.160.206 ausstehenden Aktien zum 31. Juli 2025. Die Einreichung (Nachtrag Nr. 2 zu Schedule 13D) besagt, dass Celadon beabsichtigt, vorl盲ufige Gespr盲che mit Senti 眉ber eine m枚gliche Finanzierung fortzusetzen und 脛nderungen der Kapitalstruktur sowie der Zusammensetzung des Vorstands, einschlie脽lich einer m枚glichen zus盲tzlichen Vertretung im Board, anzustreben. Celadon beh盲lt sich au脽erdem das Recht vor, Wertpapiere zu kaufen oder zu verkaufen oder Absicherungs- bzw. andere Ma脽nahmen zu ergreifen, je nach Entwicklung der Umst盲nde.
- Material stake disclosed: Celadon reports a sizeable 45.0% beneficial ownership in Senti, which can enable meaningful engagement.
- Open to financing discussions: Celadon is pursuing preliminary talks about a potential financing, which could provide capital options for Senti.
- Potential for governance disruption: Celadon may seek changes to Board composition, which could lead to contested governance actions.
- Possible capital structure changes and dilution: Discussions may include changes to Senti's capital structure, which could dilute existing shareholders.
- Market activity risk: Celadon reserves the right to buy, sell, short or hedge, which could increase share-price volatility.
Insights
TL;DR: A 45% stake gives Celadon material influence and the ability to push financing or governance changes that could reshape Senti's capital structure.
Celadon's position鈥�13.4 million shares representing 45% including warrant exercise鈥攃onstitutes a blocking/minority-controlling stake under many governance rules and creates leverage in negotiations. The filing explicitly contemplates a potential financing and changes to Board composition; those actions could materially affect equity value and dilution depending on transaction terms. The disclosure that Celadon may buy, sell, or hedge positions signals active portfolio management and potential short-term trading activity around corporate actions.
TL;DR: Celadon signals intent to engage on governance and Board representation, a materially impactful posture for Senti's corporate decision-making.
By stating it may seek additional Board representation and review strategic alternatives, Celadon has formally put the company on notice of potential governance initiatives. The explicit inclusion of Board composition and capital structure among possible topics is a standard takeover/activist playbook element; it raises the prospect of negotiated settlements, contested director elections, or agreed governance changes. The 45% beneficial ownership cap and warrant mechanics are central to how much control Celadon can legally exercise.
Celadon Partners ha dichiarato una partecipazione beneficiaria del 45,0% in Senti Biosciences, Inc. (SNTI), indicando la detenzione di 13.404.441 azioni, comprensive di 3.627.441 azioni esercitabili tramite warrant soggetti a un limite di propriet脿 del 45%. La percentuale 猫 stata calcolata su 26.160.206 azioni in circolazione al 31 luglio 2025. La comunicazione (Emendamento n. 2 al Modulo 13D) indica che Celadon intende proseguire le discussioni preliminari con Senti riguardo a un possibile finanziamento e potrebbe richiedere modifiche alla struttura del capitale e alla composizione del Consiglio, inclusa una possibile rappresentanza aggiuntiva nel Board. Celadon si riserva inoltre il diritto di acquistare o vendere titoli o di adottare operazioni di copertura o altre azioni in base all鈥檈volversi delle circostanze.
Celadon Partners revel贸 una participaci贸n beneficiaria del 45,0% en Senti Biosciences, Inc. (SNTI), reportando la posesi贸n de 13.404.441 acciones, que incluyen 3.627.441 acciones susceptibles de emitirse al ejercer warrants sujetos a un l铆mite de propiedad del 45%. El porcentaje se calcula sobre 26.160.206 acciones en circulaci贸n al 31 de julio de 2025. La presentaci贸n (Enmienda n.潞 2 al Anexo 13D) indica que Celadon pretende continuar las conversaciones preliminares con Senti sobre un posible financiamiento y podr铆a buscar cambios en la estructura de capital y en la composici贸n del Consejo, incluida la posible representaci贸n adicional en el Board. Celadon tambi茅n se reserva el derecho de comprar o vender valores o de llevar a cabo coberturas u otras acciones seg煤n evolucione la situaci贸n.
Celadon Partners電� Senti Biosciences, Inc.(SNTI)鞚� 45.0% 鞁れ 靻岇湢 歆�攵勳潉 瓿奠嫓頃橂┌ 13,404,441欤�毳� 氤挫湢頃橁碃 鞛堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞚� 欷戩棎電� 靻岇湢 頃滊弰 45%臧� 鞝侅毄霅橂姅 鞗岆煱韸� 頄夓偓搿� 氚滍枆 臧�電ロ暅 3,627,441欤�臧� 韽暔霅橃柎 鞛堨姷雼堧嫟. 牍勳湪鞚� 2025雲� 7鞗� 31鞚� 旮办 鞙犿喌 欤检嫕靾� 26,160,206欤茧ゼ 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�. 鞝滌稖靹滊(鞀れ紑欷� 13D 靾橃爼靹� 2順�)鞐� 霐半ゴ氅� Celadon鞚� 鞛犾灛鞝� 鞛愱笀臁半嫭鞐� 雽�頃� Senti鞕� 鞓堧箘 順戩潣毳� 瓿勳啀頃� 瓿勴殟鞚措┌, 鞛愲掣 甑“ 氚� 鞚挫偓須� 甑劚 氤�瓴�(於旉皜 鞚挫偓 靹犾瀯 臧�電レ劚 韽暔)鞚� 氇儔頃� 靾� 鞛堧嫟瓿� 氚濏様鞀惦媹雼�. 霕愴暅 靸來櫓 氤�頇旍棎 霐半澕 歃濌秾鞚� 毵れ垬路毵る弰頃橁卑雮� 項れ 霌� 雼るジ 臁办箻毳� 旆暊 甓岆Μ毳� 氤挫湢頃滊嫟瓿� 氇呾嫓頄堨姷雼堧嫟.
Celadon Partners a d茅clar茅 une participation b茅n茅ficiaire de 45,0 % dans Senti Biosciences, Inc. (SNTI), indiquant d茅tenir 13 404 441 actions, dont 3 627 441 actions susceptibles d鈥櫭猼re 茅mises 脿 l鈥檈xercice de warrants soumis 脿 un plafond de d茅tention de 45 %. Le pourcentage est calcul茅 sur 26 160 206 actions en circulation au 31 juillet 2025. Le d茅p么t (Amendement n掳2 au Schedule 13D) pr茅cise que Celadon a l鈥檌ntention de poursuivre les discussions pr茅liminaires avec Senti au sujet d鈥檜n 茅ventuel financement et pourrait demander des modifications de la structure du capital et de la composition du conseil d鈥檃dministration, y compris une repr茅sentation suppl茅mentaire 茅ventuelle. Celadon se r茅serve 茅galement le droit d鈥檃cheter ou de vendre des titres ou d鈥檈ngager des op茅rations de couverture ou autres selon l鈥櫭﹙olution des circonstances.
Celadon Partners gab einen wirtschaftlichen Eigentumsanteil von 45,0 % an Senti Biosciences, Inc. (SNTI) bekannt und meldete den Besitz von 13.404.441 Aktien, darunter 3.627.441 Aktien, die durch Aus眉bung von Warrants ausgebbar sind und einer Besitzobergrenze von 45 % unterliegen. Die Prozentangabe basiert auf 26.160.206 ausstehenden Aktien zum 31. Juli 2025. Die Einreichung (Nachtrag Nr. 2 zu Schedule 13D) besagt, dass Celadon beabsichtigt, vorl盲ufige Gespr盲che mit Senti 眉ber eine m枚gliche Finanzierung fortzusetzen und 脛nderungen der Kapitalstruktur sowie der Zusammensetzung des Vorstands, einschlie脽lich einer m枚glichen zus盲tzlichen Vertretung im Board, anzustreben. Celadon beh盲lt sich au脽erdem das Recht vor, Wertpapiere zu kaufen oder zu verkaufen oder Absicherungs- bzw. andere Ma脽nahmen zu ergreifen, je nach Entwicklung der Umst盲nde.
FAQ
How many SNTI shares does Celadon Partners report owning?
What percentage of Senti Biosciences does Celadon own according to the filing?
Does the reported stake include warrants or other convertible securities?
What actions does Celadon say it may pursue with respect to Senti (SNTI)?
What share count did they use to calculate the percentage ownership?
